242 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Palmer SE, et  al. Life-­threatening clozapine-­induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69:759–768.
2. Taylor D, et al. The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry. Chichester: Wiley-­Blackwell; 2021.
3. Handley SA, et  al. Clozapine-­induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992–2017. Br J Psychiatry 2022; 220:355–363.
4. Partanen JJ, et al. High burden of ileus and pneumonia in clozapine-­treated individuals with schizophrenia: a Finnish 25-­year follow-­up register study. Am J Psychiatry 2024; 181:879–892.
5. Verdoux H, et al. Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review. Schizophr Res 2019; 211:1–9.
6. Martins PLB, et al. Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: a meta-­analysis. Eur Neuropsychopharmacol 2023; 73:82–95.
7. Hung YP, et  al. Role of cytokine changes in clozapine-­induced fever: a cohort prospective study. Psychiatry Clin Neurosci 2017; 71:395–402.
8. Kohen I, et al. Increases in C-­reactive protein may predict recurrence of clozapine-­induced fever. Ann Pharmacother 2009; 43:143–146.
9. Kluge M, et  al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-­induced fever. Psychoneuroendocrinology 2009; 34:118–128.
10. Chung JP, et al. The incidence and characteristics of clozapine-­ induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53:857–862.
11. Kikuchi Y, et al. Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-­associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals. Br J Psychiatry 2024; 6:1–7.
12. Tham JC, et al. Clozapine-­induced fevers and 1-­year clozapine discontinuation rate. J Clin Psychiatry 2002; 63:880–884.
13. Taylor D, et al. Use of antacid medication in patients receiving clozapine: a comparison with other second-­generation antipsychotics. J Clin Psychopharmacol 2010; 30:460–461.
14. Van Veggel M, et al. Clozapine and gastro-­oesophageal reflux disease (GORD): an investigation of temporal association. Acta Psychiatr Scand 2013; 127:69–77.
15. Wicinski M, et al. Potential mechanisms of hematological adverse drug reactions in patients receiving clozapine in combination with proton pump inhibitors. J Psychiatr Pract 2017; 23:114–120.
16. Shuman MD, et al. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients. J Psychiatr Pract 2014; 20:50–58.
17. Humbert-­Claude M, et al. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl) 2011; 220:225–241.
18. Schoretsanitis G, et  al. Elevated clozapine concentrations in clozapine-­treated patients with hypersalivation. Clin Pharmacokinet 2021; 60:329–335.
19. Fornaro M, et al. Pharmacological interventions for antipsychotic-­related sialorrhea: a systematic review and network meta-­analysis of randomized trials. Mol Psychiatry 2023; 28:3648–3660.
20. Gonsai NH, et al. Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure. J Clin Pharm Ther 2017; 43:1–7.
21. Henderson DC, et al. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65:686–689.
22. Ronaldson KJ. Cardiovascular disease in clozapine-­treated patients: evidence, mechanisms and management. CNS Drugs 2017; 31:777–795.
23. Tanzer TD, et  al. Treatment strategies for clozapine-­induced hypotension: a systematic review. Ther Adv Psychopharmacol 2022; 12:20451253221092931.
24. Osborne IJ, et al. Clozapine-­induced myoclonus: a case report and review of the literature. Ther Adv Psychopharmacol 2015; 5:351–356.
25. Varma S, et  al. Clozapine-­related EEG changes and seizures: dose and plasma-­level relationships. Ther Adv Psychopharmacol 2011; 1:47–66.
26. Praharaj SK, et  al. Clozapine-­induced myoclonus: a case study and brief review. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:242–243.
27. Sajatovic M, et al. Clozapine-­induced myoclonus and generalized seizures. Biol Psychiatry 1996; 39:367–370.
28. Sahib Din J, et al. Knee buckling as an atypical adverse effect of clozapine: a case report. Cureus 2024; 16:e55865.
29. van der Horst MZ, et al. Isolated nausea and vomiting as the cardinal presenting symptoms of clozapine-­induced myocarditis: a case report. BMC Psychiatry 2020; 20:568.
30. Warner JP, et al. Clozapine and urinary incontinence. Int Clin Psychopharmacol 1994; 9:207–209.
31. Jeong SH, et  al. A 2-­year prospective follow-­up study of lower urinary tract symptoms in patients treated with clozapine. J Clin Psychopharmacol 2008; 28:618–624.
32. Harrison-­Woolrych M, et al. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. Br J Psychiatry 2011; 199:140–144.
33. Tanzer T, et al. Treatment strategies for clozapine-­induced nocturnal enuresis and urinary incontinence: a systematic review. CNS Spectr 2023; 28:133–144.
34. Schoretsanitis G, et  al. An update on the complex relationship between clozapine and pneumonia. Expert Rev Clin Pharmacol 2021; 14:145–149.
35. Luykx JJ, et al. Pneumonia risk, antipsychotic dosing, and anticholinergic burden in schizophrenia. JAMA Psychiatry 2024; 81:967–975.

244 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 36. Trigoboff E, et al. Sialorrhea and aspiration pneumonia: a case study. Innov Clin Neurosci 2013; 10:20–27. 37. Kuo CJ, et al. Second-­generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39:648–657. 38. Galappathie N, et  al. Clozapine-­associated pneumonia and respiratory arrest secondary to severe constipation. Med Sci Law 2014; 54:105–109. 39. Taylor DM, et  al. Reasons for discontinuing clozapine: matched, case-­control comparison with risperidone long-­acting injection. Br J Psychiatry 2009; 194:165–167. 40. Landry P, et al. Increased use of antibiotics in clozapine-­treated patients. Int Clin Psychopharmacol 2003; 18:297–298. 41. Nielsen J, et al. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol 2009; 19:483–486. 42. Raaska K, et al. Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol 2002; 58:321–322. 43. de Leon J, et  al. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1059–1063. 44. Ruan CJ, et al. Pneumonia can cause clozapine intoxication: a case report. Psychosomatics 2017; 58:652–656. 45. Leung JG, et al. Necrotizing pneumonia in the setting of elevated clozapine levels. J Clin Psychopharmacol 2016; 36:176–178. 46. de Leon J, et al. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom 2020; 89:200–214. 47. Clark SR, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res 2018; 192:50–56. 48. Hung GC, et al. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-­control study. J Clin Psychiatry 2016; 77:60–66. 49. Galappathie N, et al. Clozapine re-­trial in a patient with repeated life threatening pneumonias. Acta Biomed 2014; 85:175–179. 50. Schmidinger S, et al. Pulmonary embolism and aspiration pneumonia after reexposure to clozapine: pulmonary adverse effects of clozapine. J Clin Psychopharmacol 2014; 34:385–387. 51. Tsukahara M, et al. Impact of clozapine once-­daily versus multiple-­daily dosing regimen on relapse in patients with treatment-­resistant schizophrenia: a 1-­year retrospective cohort study. Psychopharmacology 2025; 242:161–171. 52. Sathienluckana T, et al. Comparison of the effectiveness and safety of clozapine between once-­daily and divided dosing regimen in patients with treatment-­resistant schizophrenia. Ann Pharmacother 2024; 58:598–604. 53. Sarfati D, et  al. Methylphenidate as treatment for clozapine-­induced sedation in patients with treatment-­resistant schizophrenia. Clin Schizophr Relat Psychoses 2018; doi: 10.3371/CSRP.SALA.061518. 54. Poyurovsky M, et al. Beneficial effect of betahistine, a structural analog of histamine, in clozapine-­related sedation. Clin Neuropharmacol 2019; 42:145. 55. Freudenreich O, et al. Modafinil for clozapine-­treated schizophrenia patients: a double-­blind, placebo-­controlled pilot trial. J Clin Psychiatry 2009; 70:1674–1680. 56. Fernandez-­Egea E, et al. The effect of clozapine on self-­reported duration of sleep and its interaction with 23 other medications: a 5-­year naturalistic study. J Clin Psychopharmacol 2021; 41:534–539. 57. Grover S, et al. Association of clozapine with seizures: a brief report involving 222 patients prescribed clozapine. East Asian Arch Psychiatry 2015; 25:73–78. 58. Pacia SV, et al. Clozapine-­related seizures: experience with 5,629 patients. Neurology 1994; 44:2247–2249. 59. Caetano D. Use of anticonvulsants as prophylaxis for seizures in patients on clozapine. Australas Psychiatry 2014; 22:78–83. 60. Nilsson BM, et al. Tachycardia in patients treated with clozapine versus antipsychotic long-­acting injections. Int Clin Psychopharmacol 2017; 32:219–224. 61. Nilsson BM, et al. Persistent tachycardia in clozapine treated patients: a 24-­hour ambulatory electrocardiogram study. Schizophr Res 2018; 199:403–406. 62. Stryjer R, et  al. Beta-­adrenergic antagonists for the treatment of clozapine-­induced sinus tachycardia: a retrospective study. Clin Neuropharmacol 2009; 32:290–292. 63. Lally J, et al. Pharmacological interventions for clozapine-­induced sinus tachycardia. Cochrane Database Syst Rev 2016; (6):CD011566. 64. Yuen JWY, et  al. Clozapine-­induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neurosci 2018; 12:203. 65. Lally J, et  al. Ivabradine, a novel treatment for clozapine-­induced sinus tachycardia: a case series. Ther Adv Psychopharmacol 2014; 4:117–122. 66. Shinbane JS, et  al. Tachycardia-­induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29:709–715. 67. Allison D, et al. Antipsychotic-­induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–1696. 68. Centorrino F, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002; 159:109–115. 69. Jackson A, et al. EEG changes in patients on antipsychotic therapy: a systematic review. Epilepsy Behav 2019; 95:1–9.